Sysmex Corporation · TSE:6869
Sysmex — FY2010 Earnings Presentation
24 slides from Sysmex's earnings presentation, May 11, 2010
Slide 1: Business Results for the Fiscal Year Ended March 31, 2010
Business Results for the Fiscal Year Ended March 31, 2010 Hisashi Ietsugu, President and CEO May 11, 2010
Slide 2: Contents
Contents Chapter 1 Financial Highlights for the Fiscal Year Ended March 31, 2010 Chapter 2 Consolidated Earnings Forecast for the Fiscal Year Ended March 31, 2011 Forward-looking Statements This material contains forward-looking statements about Sysmex Corporation and its group companies (the Sysmex
Slide 3: Chapter 1 Financial Highlights for the Fiscal Year Ended March 31, 2010
Chapter 1 Financial Highlights for the Fiscal Year Ended March 31, 2010
Slide 4: Financial Results
Financial Results (In billions of JPY) (In billions of JPY) 150 24 Net Sales Income FY2010 FY2010 FY2009 % over a Forecast* Year Ratio Ratio Ratio Earlier 116.1 110.7 111.8 Net Sales 116.1 100% 117.0 100% 111.8 100% 103.9% 101.0 15.7 15.0 15.1 Operating 100 87.8 13.5 16 Income 15.7 13.5% 15.0 12.8%
Slide 5: Breakdown of Net Sales and Operating Income
Breakdown of Net Sales and Operating Income (In billions of JPY) Net Sales Operating Income * FX impact excluded from Gross margin increased as a each regional sales below result of an improvement in SG&A (Direct sales and support in cost ratio increase Benelux ¥1.4billion) China AP FX impact 0.79 G
Slide 6: Breakdown of Balance Sheet
Breakdown of Balance Sheet (In billions of JPY) Assets Liabilities/Equity Fixed assets Current assets Equity Down 1.0 Retained Notes/Account Up 7.2 Others receivable earnings Intangible 0.13 Cash fixed assets Liabilities 0.94 Down 5.1 - 1.5 0.46 Up 3.2 4.3 - 3.8 7.1 - 0.59 - 1.4 Others Tangible Othe
Slide 7: Consolidated Cash Flow
Consolidated Cash Flow 25 (In billions of JPY) 21.2 ← Increase in income before income taxes and minority interests and decrease in trade notes and accounts receivable (stronger management of accounts 15 13.1 receivable) 11.6 4.4 5 0.72 - 1.3 - 0.26 -5 - 3.0 - 6.6 - 10.0 -15 - 12.8 - 13.5 Increase/d
Slide 8: Projected Dividend
Projected Dividend Interim Year-end Dividend Ratio Total Dividend Dividend （Consolidated） FY2010 Ended March 31, 2010 ¥25 ¥31 ¥56 29.4 % （Forecast） Up ¥6 from initial projection of ¥25 year- year-end dividend Note: Eighth consecutive year of dividend increases FY2009 Ended ¥24 ¥26 ¥50 31.9 % March 3
Slide 9: Topics
Topics Enhanced lineup of reagents for HISCL-2000i in the immunochemistry segment (total of 21 items) Sales of simplified test kits (POCTEM) rose substantially because of spread of pandemic flu Converted to a wholly owned subsidiary a company in Germany specializing in sales and support of POCT* pro
Slide 10: Net Sales by Geographic Region
Net Sales by Geographic Region Net Sales by (In billions of JPY) Geographical Region (Sales to Customers) FY2010 FY2009 Growth Ratio Ratio (JPY) （ Local currency ） Net Sales 116.1 100.0% 111.8 100.0% 103.9% - Americas 23.4 20.2% 23.3 20.9% 100.3% 108.6% Europe 36.4 31.4% 35.3 31.6% 103.0% 112.7% Reg
Slide 11: Geographic Segment Information: Americas
Geographic Segment Information: Americas (In billions of JPY) (In billions of JPY) 30 Operating 4.5 % over a Net Sales FY2010 FY2009 Income Year Earlier 23.3 23.4 20.8 Net Sales 23.4 23.3 100.3% 20 19.1 2.7 3 15.6 Operating Income 2.7 1.7 155.1% 1.7 * On a local currency basis: Net Sales, 108.6%; Op
Slide 12: Geographic Segment Information: Europe
Geographic Segment Information: Europe (In billions of JPY) 45 (In billions of JPY) Operating 12 % over a Net Sales FY2010 FY2009 39.1 Income Year Earlier 35.3* 36.4* 31.5 Net Sales 36.4 35.3 103.0% 30 8 25.3 5.3 Operating Income 5.3 5.1 103.3% 4.6 5.1 3.5 15 3.0 4 * On a local currency basis: Net S
Slide 13: Geographic Segment Information: China
Geographic Segment Information: China (In billions of JPY) 15 (In billions of JPY) Operating 4.5 % over a Net Sales FY2010 FY2009 Income Year Earlier 11.8 Net Sales 11.8 10.1 117.1% 10 10.1 2.7 3.0 8.1 Operating Income 2.7 1.3 210.3% 6.4 6.8 1.3 5 1.5 * On a local currency basis: Net Sales, 126.0%;
Slide 14: Geographic Segment Information: AP
Geographic Segment Information: AP (In billions of JPY) (In billions of JPY) 7.5 Net Sales Operating 1.5 % over a Income FY2010 FY2009 Year Earlier 5.8 5.3 5.0 Net Sales 5.8 5.3 108.5% 5.0 0.89 1.0 4.0 3.7 0.64 Operating Income 0.89 0.64 139.0% 0.54 * On a local currency basis: Net Sales, 116.9%; Op
Slide 15: Geographic Segment Information: Japan
Geographic Segment Information: Japan (In billions of JPY) (In billions of JPY) <Including Korea, Taiwan, and Mongolia, etc.> % over a FY2010 FY2009 Year Earlier 80 Net Sales Operating Income 20 Net Sales 66.4 69.0 96.2% 69.0 66.8 66.4 64.9 Japan 36.8 35.8 102.8% 60 59.3 15 Sales to 31.5 Customers K
Slide 16: Chapter 2 FY2011 Consolidated Earnings Forecast
Chapter 2 FY2011 Consolidated Earnings Forecast
Slide 17: External Environment
External Environment Recovery from economic crisis underway Government-led support for economic recovery Economic expansion and demand growth led by China and other emerging economies Greater investment in public healthcare services U.S. Healthcare reform bill passed – Additional 32 million people t
Slide 18: Greater Focus on Asia
Greater Focus on Asia 1997 2000 2005 2010 Global Niche No. 1 Three core Focus on Asia strategies Focus on Life Science Construction of foundation in Asia complete Built sales support network In In addition addition to to market market expansion, expansion, we we are are Expanded product portfoli
Slide 19: Geographic Segment Earnings Forecast
Geographic Segment Earnings Forecast (In billions of JPY) 18 Operating 4.5 China Net Sales Income 14.5 Use distributors to reinforce activities 11.8 as a comprehensive supplier 12 10.1 3.0 Promote sales centered on hematology analyzers 8.1 2.7 capable of analyzing five types of white blood cell 6.8
Slide 20: Geographic Segment Earnings Forecast
Geographic Segment Earnings Forecast (In billions of JPY) 30 Net Sales Operating 4.5 Americas Income 25.2 23.3 23.4 Stronger sales in hematology field, centering on 19.1 20.8 20 2.7 3.0 commercial labs and integrated healthcare networks 2.5 (IHNs) 1.7 10 1.5 0.99 Increase in reagent sales in line wi
Slide 21: Geographic Segment Earnings Forecast
Geographic Segment Earnings Forecast (In billions of JPY) <Including Korea, Taiwan, and Mongolia, etc.> Japan 90 20 Net Sales Operating Income Reinforce activities as a comprehensive supplier 75.1 Continue expansion in hematology and 66.8 69.0 66.4 hemostasis fields 64.9 15 Increase number of reagen
Slide 22: Consolidated Earnings Forecast
Consolidated Earnings Forecast FY2011 Consolidated Earnings Forecast Net Sales: ¥125 billion Operating Income: ¥17 billion Net Income: ¥10.8 billion Operating Margin: 13.6 % Net Income Margin: 8.6 % Planned exchange rate in the full year: 1US$=¥90 1EUR=¥125 (Exchange rate in the preceding full year:
Slide 23: Projected Dividend (Forecast)
Projected Dividend Interim Year-end Dividend ratio Total dividend dividend （Consolidated） FY2011ended March 31, 2011 ¥ 28 ¥ 28 ¥ 56 26.6 % （Forecast） FY2010 ended March 31, 2010 ¥ 25 ¥ 31 ¥ 56 29.4 % （Forecast） Up ¥6 from initial projection of ¥25 year-end dividend Note: Eighth consecutive year of d
Slide 24: Contact
Chapter 3 <Contact> IR & Corporate Communication Div. Phone: +81-78-265-0500 Email: info@sysmex.co.jp URL: